|
|
Article: Third Acadia, Allergan Deal Has Potential For More Than $32M.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Associate Managing Editor
Acadia Pharmaceuticals Inc. signed its third collaboration with Allergan Inc., the eye care giant, continuing a relationship that is pushing six years of existence.
"This is our largest collaboration with Allergan and it is also our third," said Douglas Richards, vice president of business development at Acadia. "Given that, it validates our platform and our approach. We are gratified by this third deal, since they have worked with us twice and are interested in working with us a third time."
The collaboration, which again will focus on eye care applications, gives Allergan the exclusive right to license chemistry and ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|